Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iotrolan. The first dimeric non-ionic contrast medium for the subarachnoid space.

B I Wenzel-Hora1

  • 1Department of Radiology I, Schering AG, Berlin, West Germany.

Acta Radiologica. Supplementum
|January 1, 1986
PubMed
Summary

Iotrolan, an iodinated contrast agent, demonstrated significantly fewer side effects compared to non-ionic monomers in intrathecal injection studies. This imaging agent showed no epileptogenic incidents or psychosyndrome symptoms, even with prolonged intracranial retention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vacuum injection--a new indirect fixing method for the demonstration of initial lymphatics in biopsy specimens of human organs.

Acta anatomica·1989
Same author

Urography with monomeric and dimeric nonionic contrast media: comparative, randomized, double-blind study of iotrolan 280 and iopromide 300.

Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband·1989
Same author

Tolerance of iotrolan 190 and cerebrospinal fluid-diluted iotrolan 300 at the same iodine concentration in lumbar myelography.

Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband·1989
Same author

Iotrolan versus iopamidol: a controlled, multicenter, double-blind study of lumbar and direct cervical myelography.

Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband·1989
Same author

Iotrolan, a nonionic dimeric contrast medium in myelography.

Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband·1989
Same author

Indirect lymphography with iotrolan.

Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband·1989

Area of Science:

  • Neuroradiology
  • Medical Imaging
  • Pharmacology

Background:

  • Intrathecal contrast agents are crucial for visualizing the spinal cord and brain.
  • Non-ionic monomers have been widely used but can cause adverse effects.
  • Evaluating new contrast agents for improved safety and efficacy is essential.

Purpose of the Study:

  • To assess the safety and efficacy of Iotrolan, a non-ionic dimeric contrast agent, for intrathecal injections.
  • To compare the incidence and severity of side effects of Iotrolan with other non-ionic monomers.
  • To evaluate potential neurological adverse events such as epileptogenic incidents and psychosyndrome symptoms.

Main Methods:

  • A clinical investigation involving 1400 in-patients and out-patients undergoing intrathecal injections.

Related Experiment Videos

  • Controlled, double-blind trials comparing Iotrolan with metrizamide, iopamidol, and iohexol at various concentrations (190, 240, 300 mg I/ml).
  • Assessment of clinicochemical, cardiovascular, and electroencephalographic parameters, along with CT scans, over a minimum of four days post-injection.

    • Main Results:

    • Iotrolan exhibited a significantly lower incidence and severity of side effects compared to non-ionic monomers.
    • No epileptogenic incidents were observed in any patient receiving Iotrolan.
    • No symptoms of a psychosyndrome were reported, even with prolonged retention of Iotrolan in intracranial fluid spaces.

    Conclusions:

    • Iotrolan represents a safer alternative to non-ionic monomers for intrathecal contrast administration.
    • The favorable safety profile of Iotrolan, particularly its lack of neurological adverse effects, is a significant advantage.
    • Iotrolan is well-tolerated for lumbar, thoracic, cervical, and intracranial imaging.